A Target Trial Emulation Study of SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Combination Therapy in Preventing Kidney Failure in Type 2 Diabetes
SGLT2 inhibitors were associated with a lower risk of kidney failure compared to GLP-1 receptor agonists. Among high-risk patients with type 2 diabetes and CKD or heart failure, combination therapy may further reduce the risk of kidney failure.
Authors
- Morgan E. Grams (ORCID: https://orcid.org/0000-0002-4430-6023)
- Donglan Zhang (ORCID: https://orcid.org/0000-0001-5225-4721)
- Aditya Surapaneni (ORCID: https://orcid.org/0000-0003-4978-5980)
- Jung‐Im Shin (ORCID: https://orcid.org/0000-0003-0374-6927)
- Sneha Mehta (ORCID: https://orcid.org/0009-0008-6226-709X)
- Matthew F. Blum (ORCID: https://orcid.org/0000-0003-4357-6926)
- Juan Jesús Carrero (ORCID: https://orcid.org/0000-0003-4763-2024)
- Lesley A. Inker (ORCID: https://orcid.org/0000-0003-2820-9482)
- Saul Blecker (ORCID: https://orcid.org/0000-0003-4460-1046)
- Leora I. Horwitz (ORCID: https://orcid.org/0000-0003-1800-6040)
Institutions
- Tufts Medical Center (US)
- University of Wisconsin–Madison (US)
- Long Island University (US)
- Johns Hopkins University (US)
- Danderyds sjukhus (SE)
- Karolinska Institutet (SE)
- Glanrhyd Hospital (GB)
- New York University (US)
Publication Details
- Journal
- Clinical Journal of the American Society of Nephrology
- Published
- 2025-11-20
- DOI
- https://doi.org/10.2215/cjn.0000000902
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00